Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2022, AN Venture Partners is a multi-stage venture capital firm based in Tokyo and San Francisco. The firm manages a $200 million fund, ANV Fund I, which closed in June 2025. AN Venture Partners focuses on enhancing Japan's biotech ecosystem by bridging it with the US startup landscape.
AN Venture Partners invests in biotech startups that stem from Japanese scientific research, with check sizes across pre-seed to Series C stages. The firm collaborates with leading global venture investors to ensure robust capitalization and support for portfolio companies, facilitating their global development.
Notable portfolio companies include Capacity Bio, developing small molecule mitophagy inducers; Typewriter Therapeutics, focused on RNA-based gene writing therapeutics; City Therapeutics, innovating in small interfering RNA (siRNA) engineering; Imbria, creating therapies for cardiometabolic disorders; PAhR Therapeutics, developing treatments for Pulmonary Arterial Hypertension; and Crystalys Therapeutics, advancing therapies for gout.
To pitch AN Venture Partners, email your deck to info@an.vc.
Yes, AN Venture Partners often leads investment rounds, particularly in early-stage biotech startups.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their strategic goals.
AN Venture Partners currently manages a $200 million fund, which is their first fund, ANV Fund I, closed in June 2025.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.